|
ONCODOC:
a successful experiment of computer-supported guideline development
and implementation in the treatment of breast cancer.
Seroussi B, Bouaud J, Antoine E. Artif Intell Med. 2001;22:43-64.
Accelerated
treatment of breast cancer.
Vicini FA, Baglan KL, Kestin LL, et al. J Clin Oncol. 2001;19:1993-2001.
Effect
of adjuvant chemotherapy on outcome in patients with metastatic
breast carcinoma treated with first-line doxorubicin-containing
chemotherapy.
Pierga JY, Asselain B, Jouve M, et al. Cancer. 2001;91:1079-89.
Polyadenylic-polyuridylic
acid plus locoregional radiotherapy versus chemotherapy with
CMF in operable breast cancer: a 14 year follow-up analysis
of a randomized trial of the Federation Nationale des Centres
de Lutte contre le Cancer (FNCLCC).
Laplanche A, Alzieu L, Delozier T, et al. Breast
Cancer Res Treat. 2001;64:189-91.
Prospective
evaluation of early cardiac damage induced by epirubicin-containing
adjuvant chemotherapy and locoregional radiotherapy in breast
cancer patients.
Meinardi
MT, van Veldhuisen DJ, Gietema JA, et al. J Clin Oncol.
2001;19:2746-53.
Bms-247550:
a novel epothilone analog with a mode of action similar to
paclitaxel but possessing superior antitumor efficacy.
Lee
FY, Borzilleri R, Fairchild CR, et al. Clin Cancer Res. 2001;7:1429-37.
The bisphosphonate,
zoledronic acid, induces apoptosis of breast cancer cells:
evidence for synergy with paclitaxel.
Jagdev SP, Coleman RE, Shipman CM, Rostami-H A, Croucher PI.
Br J Cancer. 2001;84:1126-34.
Schedule
dependency of antitumor activity in combination therapy with
capecitabine/5'-deoxy-5-fluorouridine and docetaxel in breast
cancer models.
Fujimoto-Ouchi K, Tanaka Y, Tominaga T. Clin Cancer Res. 2001;7:1079-86.
Changes
in weight, body composition, and factors influencing energy
balance among premenopausal breast cancer patients receiving
adjuvant chemotherapy.
Demark-Wahnefried
W, Peterson BL, Winer EP, et al. J Clin Oncol. 2001;19:2381-9.
Adjuvant
and neoadjuvant treatment of breast cancer [Review].
Gianni L, Valagussa P, Zambetti M, Moliterni A, Capri G, Bonadonna
G. Seminars in Oncology. 28(1):13-29, 2001 Feb.
Gemcitabine
and pemetrexed disodium in treatment breast cancer.
Adjei AA. Oncology (Huntington). 15(2 Suppl 3):34-37, 2001
Feb.
Ovarian
rescue/protection from chemotherapeutic agents.
Blumenfeld Z. Journal of the Society for Gynecologic Investigation.
8(1 Suppl S):S60-S64, 2001 Jan-Feb.
Influences
on oncologists' adoption of new agents in adjuvant chemotherapy
of breast cancer.
Buban GM, Link BK, Doucette WR. Journal of Clinical Oncology.
19(4):954-959, 2001 Feb 15.
Retreatment
of patients with the same chemotherapy: Implications for clinical
mechanisms of drug resistance [Review].
Cara S, Tannock IF. Annals of Oncology. 12(1):23-27, 2001
Jan.
Tamoxifen
and chemotherapy for axillary node-negative, estrogen receptor-negative
breast cancer: Findings from National Surgical Adjuvant Breast
and Bowel Project B-23.
Fisher B, Anderson S, Tan-Chiu E, et al. Journal of Clinical
Oncology. 19(4):931-942, 2001 Feb 15.
Angiogenesis
sustains tumor dormancy in patients with breast cancer treated
with adjuvant chemotherapy.
Gasparini G, Biganzoli E, Bonoldi E, Morabito A, Fanelli M,
Boracchi P. Breast Cancer Research & Treatment. 65(1):71-75,
2001 Jan.
Secondary
leukemia after adjuvant chemotherapy for breast cancer.
Ghalie RG, Goodkin DE. Journal of Clinical Oncology. 19(4):1231-1232, 2001 Feb 15.
Response
to cyclophosphamide, methotrexate, and fluorouracil in lymph
node-positive breast cancer according to HER2 overexpression
and other tumor biologic variables.
Menard S, Valagussa P, Pilotti S, et al. Journal of Clinical
Oncology. 19(2):329-335, 2001 Jan 15.
Excellent
response to gemcitabine in a massively pre-treated woman with
extensive cutaneous involvement after recurrence of breast
cancer.
Arends J, Unger C. Investigational New Drugs. 19(1):93-100,
2001 Feb.
Progression
and enhancement of metastatic potential after exposure of
tumor cells to chemotherapeutic agents.
De Larco JE, Wuertz BR, Manivel JC, Furcht LT. Cancer Res.
2001;61:2857-61.
Canalicular
stenosis secondary to docetaxel (taxotere): a newly recognized
side effect. Ophthalmology.
Esmaeli
B, Valero V, Ahmadi MA, Booser D. 2001;108:994-5.
Cardiac
perfusion changes in patients treated for breast cancer with
radiation therapy and doxorubicin: preliminary results.
Hardenbergh PH, Munley MT, Bentel GC, et al. Int J Radiat
Oncol Biol Phys. 2001;49:1023-8.
|
